Altre lingue Nuwellis, Inc.

Azioni

NUWE

US67113Y4052

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 03/05/2024			Variaz. 5gg	Var. 1 gen.
0,18 ^USD	-12,62%		+7,27%	-69,01%

02/05	Nuwellis, Inc. riceve dall'USPTO l'avviso di ammissione al brevetto per l'innovativa tecnologia CRRT pediatrica	CI
29/04	NUWELLIS, INC. : giudizio non più positivo da Maxim	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02/05
Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02/05
Nuwellis Announces Closing of $2.7 Million Public Offering	01/05
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024	30/04
Nuwellis Announces Pricing of $2.7 Million Public Offering	26/04
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09/04
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09/04
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference	07/03
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days	07/03
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	06/03
Earnings Flash (NUWE) NUWELLIS Reports Q4 Revenue $2.6M	05/03
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results	05/03
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	27/02
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™	22/02
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/02
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference	20/02
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload	06/02
Certain Warrants of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01
Certain Stock Options of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01
Certain Common Stock of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nuwellis, Inc.

Azioni

NUWE

US67113Y4052

Altre lingue

Filtri